GENA-104 / Genome & Company - LARVOL DELTA

Genome & Company announces 4 preclinical results of 'GENA-104' at 2024 AACR [Google translation] (HIT News) - "Genome & Company...will announce the preclinical results of 'GENA-104 (development code name)'...at the American Association for Cancer Research...to be held in San Diego, California, USA from the 5th of next month. It was announced on the 6th that four cases will be presented as posters...The GENA-104 preclinical results to be announced this time include; Exploration of CNTN4 expression rate in 18 carcinomas through artificial intelligence (AI)-based immunohistochemical staining (IHC) analysis and correlation with PD-L1 expression; Keytruda (ingredient pembrolizumab) ) In-depth analysis of CNTN4 expression in gastric cancer patients who received; The expression mechanism in T cells of the new target APP, a CNTN4 binding partner, and expression analysis results in patients who did not respond to existing immunotherapy drugs; The possibility of CNTN4 as a new ADC target is confirmed. Two of these cases were jointly researched with Lunit, a medical artificial..."

Preclinical • Oncology

Genome & Company, immuno-oncology drug 'GENA-104' approved for phase 1 clinical trial in Korea [Google translation] (HIT News) - "Genome & Company (CEO Bae Ji-so and Park Han-so) announced on the 10th that its new target immuno-oncology drug 'GENA-104 (development code name)' has received approval from the Ministry of Food and Drug Safety for its Phase 1 clinical trial plan (IND)....The company plans to conduct the Phase 1 clinical trial in patients with solid tumors. A dose escalation cohort will be conducted to demonstrate safety and tolerability, and to confirm efficacy."

New P1 trial • Oncology • Solid Tumor

Genome & Company, CNTN4 targeted immune anti-cancer drug, excellent project for national new drug development project [Google translation] (HIT News) - "Genome & Company...has announced that its new target immuno-anticancer drug 'GENA-104 (development code name)' has been selected as one of the top 10 National New Drug Development Project Group (Director Muk Hyeon-sang, hereinafter referred to as the project group). It was announced on the 13th that it was selected as an excellent project....GENA-104, which was selected as an excellent project, is an immunotherapy candidate targeting CNTN4, a new target discovered by Genome & Company."

Preclinical • Oncology

Genome & Company, breaking away from the microbiome 'one tool'… 'Technology transfer of anti-cancer drugs within the year' [Google translation] (HIT News) - "Genome & Company plans to transfer technology within the year for new target anticancer drugs...The pipelines announced for technology transfer within the year at the meeting were 'GENA-104 (development code name)' and 'GENA-111'...CEO Bae explained that he is currently discussing a specific term sheet with global pharmaceutical companies for the pipeline....Based on the results of confirming the possibility of such development, the company predicted that it would submit a phase 1 clinical trial plan (IND) for GENA-104 within the third quarter."

Commercial • IND • New P1 trial • Oncology • Solid Tumor

K-Bio, a large number of AACR launches… active search for new drug candidates [Google translation] (Medical Observer) - "Genome & Company will disclose three preclinical study results of 'GENA-104', a new immuno-oncology drug candidate....For Abion, a total of five research results, including ABN401, were adopted as official presentation topics at AACR....Abion will unveil the results of non-clinical brain metastasis studies at this AACR....As a result of observation, ABN401 was found to be competitive in anticancer efficacy and safety compared to existing approved drugs for non-small cell lung cancer patients. In addition, non-clinical results of the combination of ABN401 and KRAS-targeted therapy will be disclosed."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Genome & Company "Phase 2 GEN-001 gastric cancer combination, announcement of interim results in the first half" [Google translation] (HIT News) - "Genome & Company is also accelerating the development of GENA-104, a new targeted immuno-oncology drug. GENA-104 is a new target (CNTN-4)-based immuno-anticancer drug expressed in cancer cells. According to the company, it is aiming for phase 1 IND approval within the first half of this year."

IND • Oncology

Novel immune checkpoint protein CNTN4 and the preclinical efficacy of affinity matured anti-CNTN4 antibody GENA-104A16 (AACR 2022) - "In addition, we confirmed that CNTN4 is highly expressed on the various types of human tumor tissue, and anti-CNTN4 antibodies, GENA-104A07 and GENA-104A11, show the anti-tumor efficacy by enhancing T cell activity. Interestingly, GENA-104A16 treatment showed better anti-tumor effects together with the elevated level of CD8+ T cells expressing perforin and granzyme B than atezolizumab treatment. Overall, these preclinical studies demonstrate that GENA-104A16 is a promising blocking antibody for CNTN4-mediated immune suppression and can serve as an effective immune-oncology drug for patients with cancer that highly express CNTN4."

IO biomarker • Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • APP • CD4 • CD8 • CNTN • FOXP3 • GZMB • IL2RA

[VIRTUAL] Anti-CNTN4 antibody, GENA-104A07 suppresses tumor growth in murine syngeneic tumor models by regulating T cell function (AACR 2021) - "Taken together with in vitro and in vivo studies, the efficacy of GENA-104A07 demonstrated that CNTN4 blockage with monoclonal antibody may provide an immunotherapeutic strategy for human cancer. Currently, the preliminary safety study is ongoing in mice, and IND enabling studies will be initiated early next year with the optimized antibody."

IO biomarker • Preclinical • Oncology • CNTN

Korean drugmakers aim to export technology during US cancer convention (Korea Biomedical Review) - "Despite the protracted Covid-19 pandemic, many Korean biopharmaceutical companies plan to participate in the 2021 American Association for Cancer Research (AACR)...Medpacto will also present the preclinical results of the combination therapy of Vactosertib and Onivyde for treating pancreatic cancer and the research results of BAG2 and DRAK1, the follow-up pipelines of Vactosertib. Genome & Company will unveil the research results of GICP-104...,GNOCLETM, and animal test results of GENA-104, a new target anticancer drug that suppresses GICP-104, for the first time."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer